Inventiva (NASDAQ:IVA) Shares Gap Down – Should You Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped down before the market opened on Wednesday . The stock had previously closed at $3.97, but opened at $3.74. Inventiva shares last traded at $3.8510, with a volume of 95,913 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on IVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Truist Financial began coverage on shares of Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $16.56.

Inventiva Stock Down 4.7%

The firm’s fifty day moving average is $5.17 and its 200 day moving average is $5.40.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The company had revenue of $0.01 million for the quarter. As a group, analysts expect that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Inventiva

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paradigm Biocapital Advisors LP purchased a new stake in Inventiva in the 4th quarter worth $18,600,000. ADAR1 Capital Management LLC acquired a new stake in Inventiva during the 4th quarter worth $12,601,000. Millennium Management LLC boosted its stake in Inventiva by 2,267.7% during the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock worth $12,334,000 after purchasing an additional 2,540,540 shares during the last quarter. UBS Group AG boosted its stake in Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new stake in Inventiva during the 4th quarter worth $12,090,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.